Uncategorized
calendar_month Nov 18, 2026

Capricor Stock in Focus Ahead of FDA Decision on Duchenne Therapy Deramiocel

Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are in the spotlight Wednesday as investors position ahead of the FDA’s decision on deramiocel, the company’s cell therapy for Duchenne muscular dystrophy, set for Nov. 22.

FDA Decision Looms After Major BLA Amendment

The FDA extended its review of Capricor’s Biologics License Application by three months after classifying an August submission as a major amendment. That filing added two-year open-label extension data from the Phase 3 HOPE-3 trial, additional robustness analyses and an integrated efficacy summary across HOPE-2 and HOPE-3.

Capricor also proposed a narrower indication focused on upper limb impairment in patients older than 9, the population studied in HOPE-3 and the focus of its primary endpoint.

As part of the review, the FDA conducted a clinical trial inspection in July and issued a Form 483 with one observation. Capricor has submitted its response and is awaiting feedback from the agency.

Two-Year Data Shows 76% Slower Upper Limb Decline

In the open-label extension, patients who switched from placebo to deramiocel after one year declined 1.56 points less on the Performance of the Upper Limb (PUL 2.0) scale than during their year on placebo, a 76% slowing. Patients treated with deramiocel from the start maintained a slower rate of decline over two years, which the company said supports the durability of the treatment effect.

Capricor’s HOPE-3 cardiac results also received the American Heart Association’s Outstanding Research Award in Pediatric Cardiology, with data showing slower progression of heart muscle scarring with deramiocel versus placebo.

“With our San Diego facility operational, we are prepared to move quickly to bring Deramiocel to patients, if approved,” said CEO Linda Marbán.

Q3 Loss Widens as Launch Spending Ramps

Capricor reported a third-quarter loss of 73 cents per share last week, wider than the consensus estimate of a loss of 5 cents. The company recorded no revenue in the quarter.

Total operating expenses climbed to about $44.7 million from $26.3 million a year earlier, driven by pre-commercial activities and manufacturing scale-up. Capricor also cut about 10% of its workforce during the quarter to reduce expenses.

Capricor ended the quarter with about $198.5 million in cash, cash equivalents, restricted cash and marketable securities, down from $318.1 million at the end of 2025. The company said that balance is enough to fund operations for at least the next 12 months and that it has not sold any shares under its at-the-market program this year.

Capricor Shares Edge Higher

CAPR Price Action: Capricor shares were up 4.04% at $8.75 at the time of publication Wednesday, according to Benzinga Pro data.

Image via Shutterstock